Clinical trials: Drug-drug Interaction
Healthy
DDI Study With Multiple-dose LX4211 and Single Dose Digoxin
This study will be conducted as a single-center, open-label, 2-period, single-sequence, drug-drug interaction study to assess the effects of multiple dose LX4211 (400 mg administered as 2 × 200-mg tablets qd × 12 days) on the PK…
- Trial name
- NCT02300350
- Testing
- Treatment A digoxin, Treatment B LX4211, Treatment C Digoxin + 400 mg LX4211 administered concomitantly
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Healthy Adult Female Participants
A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants
The objective of this study is to evaluate the effect of multiple oral doses of vorasidenib on the single dose pharmacokinetics of the representative combined oral contraceptive, drospirenone (DRSP)/ethinyl estradiol (EE), in…
- Trial name
- NCT07235774
- Testing
- Vorasidenib, DRSP/EE
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Institut de Recherches Internationales Servier (I.R.I.S.)
Healthy
Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects
This is a double-blind, randomised, placebo-controlled 3 period study to evaluate the interaction between a drug and CNV1014802 in healthy male and female subjects. It is planned to enrol 36 subjects.
- Trial name
- NCT02551497
- Testing
- CNV1014802
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy
A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants
The purpose of this study is to evaluate effect of multiple-dose administration of JNJ-42847922 on the single-dose pharmacokinetics of oral midazolam and single-dose pharmacokinetics and pharmacodynamics of (R)- and (S)-warfarin…
- Trial name
- NCT02617810
- Testing
- JNJ-42847922, Midazolam, Warfarin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers
A single 125 mg oral dose of the investigational compound PD-0332991 will be administered alone and after steady-state dosing of tamoxifen to determine if coadministration of tamoxifen alters the plasma pharmacokinetics of…
- Trial name
- NCT01821066
- Testing
- PD-0332991 alone, Tamoxifen 60 mg, Tamoxifen 20 mg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Male Volunteers
Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802
The purpose of this study is to evaluate the drug-drug interaction between LGEV1801 and LGEV1802 in healthy male volunteers.
- Trial name
- NCT03532854
- Testing
- Valsartan, Ezetimibe/Rosuvastatin
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- LG Chem
Spinal Muscular Atrophy
A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants
This will be a Phase I, 2-part, open-label, non-randomized study to investigate the safety, tolerability, and pharmacokinetics (PK) of a multiple-dosing regimen of risdiplam (Part 1) and the effect of risdiplam on the PK of…
- Trial name
- NCT03988907
- Testing
- Risdiplam, Midazolam
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Malaria
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole
The study will assess the effect of multiple doses of itraconazole, a strong CYP3A4/5 inhibitor, on the PK of ganaplacide and lumefantrine in healthy participants.
- Trial name
- NCT05084651
- Testing
- Ganaplacide, Lumefantrine, Itraconazole
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Clinical Trial, Phase I
Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan
This is a study in postmenopausal women to investigate the Drug-drug interaction (DDI) between itraconazole(ITZ) and orally administered vilaprisan; absolute bioavailability using intravenous microtracer dose of [14C]vilaprisan.
- Trial name
- NCT02456129
- Testing
- Vilaprisan (BAY1002670), [14C] Vilaprisan, Itraconazole(ITZ)
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Pharmacokinetics
Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects
The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine SR on the pharmacokinetics of Tamoxifen and endoxifen when coadministered to healthy post-menopausal female subjects.
- Trial name
- NCT01189500
- Testing
- Tamoxifen, Tamoxifen and Desvenlafaxine Succinate Sustained Release
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypertension, Hyperlipidemia
Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers
Primary objective : To investigate pharmacokinetics after concomitant administration of valsartan and rosuvastatin compared to single administration of valsartan or rosuvastatin in healthy male volunteers Secondary objective : To…
- Trial name
- NCT01918709
- Testing
- Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R), Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R), Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Drug-Drug Interaction Healthy Volunteers
A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers
The primary aim of this Phase 1 study is to evaluate the effect of vapendavir daily doses of 528 mg daily (QD) and 264 mg twice daily (BID) on the pharmacokinetic (PK) profile of midazolam, a cytochrome (CYP) 3A4 substrate.
- Trial name
- NCT02204501
- Testing
- Midazolam 5mg Syrup, Vapendavir 264 mg BID, Vapendavir 528 mg QD
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Biota Scientific Management Pty Ltd
Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity.
- Trial name
- NCT07785934
- Testing
- UBT251, Metformin hydrochloride, Warfarin Sodium
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Infections, Human Immunodeficiency Virus and Herpesviridae
GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir
GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-1 infection by GlaxoSmithKline (GSK) on behalf of Shionogi-ViiV HealthcareLLC.
- Trial name
- NCT01209065
- Testing
- GSK1349572, Fosamprenavir, Ritonavir
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients
The purpose of this study is to see how the body processes 1592U89 and ethanol (pure grain alcohol) when they are given together.
- Trial name
- NCT00002198
- Testing
- Abacavir sulfate
- Where
- United States
- Sponsor
- Glaxo Wellcome
Opioid Use Disorder
Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).
The purpose of the study is to assess drug-drug interaction (DDI) and safety of AZD4041 and itraconazole in healthy participants (Part 1), and to assess efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD404…
- Trial name
- NCT06406400
- Testing
- AZD4041, Itraconazole, Buprenorphine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- AstraZeneca
Human Immunodeficiency Virus Infection
A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
The study is a single-centre, open-label, fixed-sequence, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects. Subjects will take SHR2150 on Day 1 and Day 21, and take efavirenz from Day 7 to Day 26.
- Trial name
- NCT05141422
- Testing
- SHR2150 tablet、efavirenz
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy Female Adults
A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants
The purpose of this study is to assess the food effect and drug interactions on drug levels of Navlimetostat in health adult female participants
- Trial name
- NCT07800897
- Testing
- Navlimetostat, Itraconazole, Rifampin
- Where
- Canada
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Infection, Human Immunodeficiency Virus
A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176
The purpose of this study is to evaluate how BMS955176 affects pharmacokinetics (PK) of Dolutegravir (DTG) and also how DTG administration affects the PK of BMS955176
- Trial name
- NCT02715479
- Testing
- Dolutegravir, BMS955176
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy Male Subjects
A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects
An open-label, single-center, single-sequence study to evaluate the drug-drud interaction between the CYP3A substrate triazolam and TS-172 (part A) and the potent CYP3A inhibitor itraconazole and TS-172 (part B) in healthy male…
- Trial name
- NCT06837142
- Testing
- Triazolam and TS-172, TS-172 and itraconazole
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.